In a Phase Ib/II trial (NCT04194801) assessing the combination of BLU-554 and the anti-PD-L1 monoclonal antibody CS1001 for the treatment of locally advanced or metastatic HCC, 4 FGF19-positive patients were administered BLU-554 (600 mg once daily) alongside CS1001 (1200 mg every three weeks), achieving an ORR of 50% and a DCR of 100%. This evidence concerns the gene FGF19 and hepatocellular carcinoma.